188 related articles for article (PubMed ID: 36823670)
21. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
[TBL] [Abstract][Full Text] [Related]
22. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
23. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
[TBL] [Abstract][Full Text] [Related]
24. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Rischin D; Hughes BGM; Basset-Séguin N; Schadendorf D; Bowyer S; Trabelsi Messai S; Meier F; Eigentler TK; Casado Echarren V; Stein B; Beylot-Barry M; Dalac S; Dréno B; Migden MR; Hauschild A; Schmults CD; Lim AM; Yoo SY; Paccaly AJ; Papachristos A; Nguyen JH; Okoye E; Seebach F; Booth J; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471711
[TBL] [Abstract][Full Text] [Related]
25. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
26. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
27. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
28. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
29. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
30. Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review.
Banini M; Salvestrini V; Vultaggio A; Perlato M; Mecheri V; Cerbai C; Scotti V; Matucci A; Mangoni M; Livi L; Bonomo P
Curr Oncol; 2023 Jul; 30(7):6699-6707. PubMed ID: 37504351
[TBL] [Abstract][Full Text] [Related]
31. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
32. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study.
Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444
[TBL] [Abstract][Full Text] [Related]
33. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
[TBL] [Abstract][Full Text] [Related]
34. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer.
Nguyen JH; Epling D; Dolphin N; Paccaly A; Conrado D; Davis JD; Al-Huniti N
CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1458-1471. PubMed ID: 36251220
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Kaufman HL; Seebach F; Lowy I; Yoo SY; Mathias M; Fenech K; Han H; Fury MG; Rischin D
N Engl J Med; 2022 Oct; 387(17):1557-1568. PubMed ID: 36094839
[TBL] [Abstract][Full Text] [Related]
37. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?
Soura E; Gagari E; Stratigos A
Curr Opin Oncol; 2019 Sep; 31(5):461-468. PubMed ID: 31394558
[TBL] [Abstract][Full Text] [Related]
38. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma.
Valentin J; Gérard E; Ferte T; Prey S; Dousset L; Dutriaux C; Beylot-Barry M; Pham-Ledard A
J Geriatr Oncol; 2021 Sep; 12(7):1110-1113. PubMed ID: 33736973
[TBL] [Abstract][Full Text] [Related]
39. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: a retrospective analysis.
Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38885840
[TBL] [Abstract][Full Text] [Related]
40. Oral ulcers and sarcoid-like reaction in lymph nodes after cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma: a case report.
Ferreira MH; Bezinelli LM; Eduardo FP; Gobbi MF; Corrêa L; Schvartsman G
Einstein (Sao Paulo); 2022; 20():eRC6367. PubMed ID: 35303053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
